Vaccines for COVID-19 in patients with atopic dermatitis: three things every dermatologist should know

Acta Dermatovenerol Alp Pannonica Adriat. 2021 Jun;30(2):67-69.

Abstract

Almost 13 months have passed since the World Health Organization (WHO) declared the coronavirus disease 19 (COVID-19) pandemic, caused by the SARS-CoV-2, on March 11th, 2020. During this period, we have realized that the most effective weapon we have to prevent SARS-CoV-2 infection, or to make it less aggressive, is vaccines. Currently, according to the WHO document "Draft landscape of COVID-19 candidate vaccines," there are 275 vaccines in development against the virus, although at the moment there are four preparations in distribution in the United States and in Europe. The characteristics of these vaccines are quite different from each other and may even be unfamiliar in the medical field. In particular, among dermatologists, knowledge of vaccines is of fundamental importance, especially in atopic dermatitis. Atopic patients are aware of having a predisposition to develop allergies, and so they are asking dermatologists about the safety of the vaccines currently available against the SARS-CoV-2. This article provides an up-to-date overview of this topic by reviewing current literature and sharing our personal experience.

MeSH terms

  • COVID-19 / prevention & control*
  • COVID-19 Vaccines / adverse effects
  • COVID-19 Vaccines / therapeutic use*
  • Clinical Competence
  • Dermatitis, Atopic / etiology*
  • Dermatitis, Atopic / prevention & control
  • Dermatologists / standards*
  • Europe
  • Humans
  • Practice Patterns, Physicians' / standards*

Substances

  • COVID-19 Vaccines